A new health care index predicts short term mortality for TB and HIV co-infected people
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
A new health care index predicts short term mortality for TB and HIV co-infected people. / Roen, A. O.; Podlekareva, D.; Miller, R. F.; Mocroft, A.; Panteleev, A.; Skrahina, A.; Miro, J. M.; Cayla, J. A.; Tetradov, S.; Derisova, E.; Furrer, H.; Losso, M. H.; Vassilenko, A.; Girardi, E.; Lundgren, J. D.; Post, F. A.; Kirk, O.
I: International Journal of Tuberculosis and Lung Disease, Bind 24, Nr. 9, 2020, s. 956-962.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A new health care index predicts short term mortality for TB and HIV co-infected people
AU - Roen, A. O.
AU - Podlekareva, D.
AU - Miller, R. F.
AU - Mocroft, A.
AU - Panteleev, A.
AU - Skrahina, A.
AU - Miro, J. M.
AU - Cayla, J. A.
AU - Tetradov, S.
AU - Derisova, E.
AU - Furrer, H.
AU - Losso, M. H.
AU - Vassilenko, A.
AU - Girardi, E.
AU - Lundgren, J. D.
AU - Post, F. A.
AU - Kirk, O.
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Using 2004–2007 TB:HIV Study data from Europe and Latin America, we previously generated a health care index (HCI) for TB and HIV co-infected people. With improvements in diagnostic and management practices, we have now updated the HCI with new data. METHODS: We evaluated nine aspects of health care in Cox proportional hazards models on time from TB diagnosis to death. Kaplan-Meier methods were used to estimate the probability of death by HCI quartile. RESULTS: Of 1396 eligible individuals (72% male, 59% from Eastern Europe), 269 died within 12 months. Use of rifamycin/isoniazid/pyrazinamide-based treatment (HR 0.67, 95% CI 0.50–0.89), TB drug susceptibility testing (DST) and number of active TB drugs (DST þ,3 drugs (HR 1.09, 95% CI 0.80–1.48), DST þ ≥3 drugs (HR 0.49, 95% CI 0.35–0.70) vs. no DST), recent HIV-RNA measurement (HR 0.64, 95% CI 0.50–0.82) and combination antiretroviral therapy use (HR 0.72, 95% CI 0.53–0.97) were associated with mortality. These factors contributed respectively 5, –1, 8, 5 and 4 to the HCI. Lower HCI was associated with an increased probability of death; 30% (95% CI 26–35) vs. 9% (95% CI 6–13) in the lowest vs. the highest quartile. CONCLUSION: We found five potentially modifiable health care components that were associated with mortality among TB-HIV positive individuals. Validation of our HCI in other TB cohorts could enhance our findings.
AB - BACKGROUND: Using 2004–2007 TB:HIV Study data from Europe and Latin America, we previously generated a health care index (HCI) for TB and HIV co-infected people. With improvements in diagnostic and management practices, we have now updated the HCI with new data. METHODS: We evaluated nine aspects of health care in Cox proportional hazards models on time from TB diagnosis to death. Kaplan-Meier methods were used to estimate the probability of death by HCI quartile. RESULTS: Of 1396 eligible individuals (72% male, 59% from Eastern Europe), 269 died within 12 months. Use of rifamycin/isoniazid/pyrazinamide-based treatment (HR 0.67, 95% CI 0.50–0.89), TB drug susceptibility testing (DST) and number of active TB drugs (DST þ,3 drugs (HR 1.09, 95% CI 0.80–1.48), DST þ ≥3 drugs (HR 0.49, 95% CI 0.35–0.70) vs. no DST), recent HIV-RNA measurement (HR 0.64, 95% CI 0.50–0.82) and combination antiretroviral therapy use (HR 0.72, 95% CI 0.53–0.97) were associated with mortality. These factors contributed respectively 5, –1, 8, 5 and 4 to the HCI. Lower HCI was associated with an increased probability of death; 30% (95% CI 26–35) vs. 9% (95% CI 6–13) in the lowest vs. the highest quartile. CONCLUSION: We found five potentially modifiable health care components that were associated with mortality among TB-HIV positive individuals. Validation of our HCI in other TB cohorts could enhance our findings.
KW - Health care index
KW - HIV
KW - TB
U2 - 10.5588/ijtld.19.0568
DO - 10.5588/ijtld.19.0568
M3 - Journal article
C2 - 33156764
AN - SCOPUS:85095802544
VL - 24
SP - 956
EP - 962
JO - International Journal of Tuberculosis and Lung Disease
JF - International Journal of Tuberculosis and Lung Disease
SN - 1027-3719
IS - 9
ER -
ID: 256219027